Chloé Bertolus, Alain Viari, Pierre Saintigny, Sophie Deneuve, Emilie Sohier, Scott M. Lippman, William Williams, Jean-Philippe Foy, Janice Kielbassa, Alain Puisieux, Patrick Goudot, Wenhua Lang, Solène Destandau, Geneviève De Souza, Emilie Thomas, Marie-Alexandra Albaret, Li Mao, Sandra Ortiz-Cuaran, Christophe Caux, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC), Department of Translational Research and Innovation, Centre Léon Bérard, MD Anderson Cancer Center [Houston], The University of Texas Health Science Center at Houston (UTHealth), Synergie Lyon Cancer-Platform of Bioinformatics-Gilles Thomas, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Translational research and innovation department [Lyon], Centre Léon Bérard [Lyon], Equipe de recherche européenne en algorithmique et biologie formelle et expérimentale (ERABLE), Inria Grenoble - Rhône-Alpes, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Unité de recherche Neuroépidémiologie [CHU Pitié-Salpêtrière], Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Lung Cancer Center, Johnson & Johnson, Moores Cancer Center [La Jolla], UC San Diego School of Medicine, Department of Medical Oncology [Lyon], This work was supported by the Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA) 2014-2016 Structured Program [Grant numberCVPPRCAN000153/International Head and Neck Prevention Act-IHNPACT to P.S.), the LYric Grant INCa-DGOS-4664 andProjets libresde recherche «Biologie et Sciences du Cancer»–INCa-PLBIO17-338, Annéerecherche-Assistance Publique des Hôpitaux de Paris (J.P.F.), «Soutienpour la formation à la recherche translationnelle en cancérologie» fromINCa and AVIESAN (J.P.F), Fondation Synergie Lyon-Cancer, S.M.L. wassupported for this work by NCI P30-CA023100-29, NCIHHSN2612012000311, R01DE026644-01Cancéropôle Lyon AuvergneRhône-Alpes(CLARA)2014-2016StructuredProgram[CVPPRCAN000153], LYric Grant [INCa-DGOS-4664], Projets libres derecherche [INCa-PLBIO17-338], Targeting Signaling Vulnerabilities forOral Cancer Prevention [R01DE026644-01], Fondation Synergie Lyon-Cancer [N/A], Grant from NCI [NCI P30-CA023100-29], Grant fromNCI [NCI HHSN2612012000311], Année recherche - Assitance Publique des Hôpitaux de Paris [N/A, N/A], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), School of Medicine [Univ California San Diego] (UC San Diego), University of California [San Diego] (UC San Diego), University of California (UC)-University of California (UC)-University of California [San Diego] (UC San Diego), and University of California (UC)-University of California (UC)
International audience; Oral squamous cell carcinoma (OSCC) is a major cause of cancer-associated morbidity and mortality and may develop from oral premalignant lesions (OPL). An improved molecular classification of OPL may help refining prevention strategies. We identified two main OPL gene-expression subtypes, named immunological and classical, in 86 OPL (discovery dataset). A gene expression-based score was then developed to classify OPL samples from three independent datasets, including 17 (GSE30784),13 (GSE10174) and 15 (GSE85195) OPLs, into either one of the two gene-expression subtypes. Using the single sample gene set enrichment analysis, enrichment scores for immune-related pathways were different between the two OPL subtypes. In OPL from the discovery set, loss of heterozygosities (LOH) at 3p14, 17p13, TP53, 9p21 and 8p22 and miRNA gene expression profiles were analyzed. Deconvolution of the immune infiltrate was performed using the Microenvironment Cell Populations-counter tool. A multivariate analysis revealed that decreased miRNA-142-5p expression (P = 0.0484) and lower T-cell, monocytic and myeloid dendritic cells (MDC) immune infiltration (T-cells, P = 0.0196; CD8 T cells, P = 0.0129; MDC, P = 0.0481; and monocytes, P = 0.0212) were associated with oral cancer development in the immunological subtype only. In contrast, LOH at 3p14 (P = 0.0241), 17p13 (P = 0.0348) and TP53 (P = 0.004) were associated with oral cancer development in the classical subtype only. In conclusion, we identified 2 subtypes of OPLs, namely immune and classical, which may benefit from different and specific personalized prevention interventions. ARTICLE HISTORY